

Xhale Issued U.S Patent for Breath-Based Closed-Loop Propofol Monitoring

Xhale, Inc. announced today the issuance of U.S. patent 8,211,035, disclosing a non-invasive method of monitoring and controlling propofol and other IV-administered agents utilizing a breath detection system.

Gainesville, FL July 3, 2012

Xhale, Inc. announced today the issuance of U.S. Patent 8,211,035, disclosing methods and apparatuses for the detection, quantitation, and trending of intravenous (IV) and/or inhalational delivered drug concentration(s) utilizing a breath detection system. This non-invasive system enables the monitoring of the intravenous anesthetic propofol via exhaled breath, controlling the delivery of the desired dose of propofol or other drugs to a patient. The system comprises a breath analyzer for analyzing the patient's breath for concentration of the agents, and a control mechanism that delivers propofol or other drugs based on the concentrations in exhaled breath.

A major impediment to the wider use of the IV anesthetic propofol, has been the inability to precisely determine the quantity required to provide a sufficient anesthesia without accumulating an excessive amount. Medications are ineffective if blood concentration levels are too low, and can be toxic when concentrations are too high. Currently, there is no technology to measure the concentration of propofol in blood in real-time. Xhale's newly patented system would provide the correlation to blood levels effectively in real-time.

"This provides a more predictive method to monitor blood propofol concentration," explained Dr. Richard J. Melker, M.D., Ph.D., Xhale's Chief Technology Officer. "The system enables the user to immediately and continuously monitor the blood concentration of propofol, inhalation anesthetics and other medications routinely delivered to eliminate pain".

Xhale is a medical technology innovator, developing products that transform healthcare and save lives. The company is a world leader in the use of sensors that analyze vapor in exhaled breath and is focused on novel patient-centric monitoring solutions. Among its product lines under development are SMART™, the world's only definitive medication adherence monitoring system, and Assurance™, a replacement for conventional finger-based pulse oximetry which will monitor multiple patient parameters from a single-point-of-contact sensor, more comfortably and conveniently than finger-based pulse oximetry with fewer false alarms.

For more information, please visit www.xhale.com or contact the company at 352.371.8488.
